相关实验视频

Updated: Jun 12, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

聚合PD1/PDL1双特异抗体增强免疫检查点阻塞疗法

Fuxin Xue¹, Xitong Ren², Chaoying Kong²

¹Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, 130033, China.

Materials today. Bio

|September 25, 2024

概括

一种针对PD1/PDL1的新型聚合二特异性抗体增强了免疫检查点阻塞 (ICB) 疗法. 这种新的方法显著抑制了瘤生长,并在临床前模型中改善了生存率.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

免疫检查点阻塞 (ICB) 治疗,包括PD1/PDL1抑制,显示出希望,但对许多患者的应答率低于30%.
提高ICB的疗效对于改善癌症治疗中的持久反应至关重要.

研究的目的:

开发和评估一种针对PD1和PDL1的新型聚合双特异抗体 (BsAb),以改善ICB治疗.
在临床前癌症模型中研究双目标BsAb的机制和疗效.

主要方法:

聚L-胺酸 (PGLU) 与Fc结合 (Fc-III-4C) 的结合,形成一个聚合物骨干.
将结合物与抗PD1 (αPD1) 和抗PDL1 (αPDL1) 单克隆抗体 (mAbs) 混合,形成BsAb_αPD1+αPDL1.
在结肠癌小鼠模型中评估BsAb在抑制瘤生长和延长存活的疗效.

主要成果:

PD1/PDL1 BsAb作为桥梁,持续激活CD8+ T细胞,比单个mAbs或自由mAb混合物更有效.
在结肠癌小鼠模型中,在48天后实现了90.1%的瘤抑制率和83.3%的生存率.
与传统的ICB治疗相比,已经证明了更高的抗瘤活性.

结论:

开发出来的BsAb_αPD1+αPDL1功能是同步T细胞参与者和双重免疫检查点抑制剂.
这种新的双特异性抗体策略为加强临床ICB治疗提供了有希望的方法.
这些发现为开发更有效的癌症免疫疗法提供了理论指导.

关键词:

双特异性抗体双特异性抗体癌症免疫疗法癌症免疫疗法这是一种Fc结合.发生PD1/PDL1阻塞.一个T细胞参与者.

更多相关视频

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...